Shanghai Henlius Biotech (HKG:2696) will grant Alvogen Korea an exclusive license to commercialize HANSIZHUANG (serplulimab injection) in South Korea, a Friday Hong Kong bourse filing said.
Alvogen Korea will make an upfront payment of $5 million, along with regulatory and commercial milestone payments, and will pay tiered royalties.
The drug will be commercialized for the treatment of various forms of cancer including lung cancer, colorectal cancer, gastric cancer, and esophageal squamous cell carcinoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.